Comentario del CEIPV a las nuevas Guías Europeas de Prevención Cardiovascular 2021
- Brotons, Carlos
- Camafort, Miguel
- Castellanos, María del Mar 1
- Clarà, Albert 2
- Cortés, Olga
- Diaz Rodriguez, Angel
- Elosua, Roberto
- Gorostidi, Manuel 3
- Hernández, Antonio M. 4
- Herranz, María
- Justo, Soledad
- Lahoz, Carlos
- Niño, Pilar 5
- Pallarés-Carratalá, Vicente
- Pedro-Botet, Juan
- Pérez Pérez, Antonio
- Royo-Bordonada, Miguel Angel
- Santamaria, Rafael
- Tresserras, Ricard
- Zamora, Alberto
- Zuza, Inés 6
- Armario, Pedro
- 1 Sociedad Española de Neurología, Barcelona, España
- 2 Sociedad Española de Angiología y Cirugía Vascular, Madrid, España
- 3 Sociedad Española de Nefrología, Santander, España
- 4 Sociedad Española de Diabetes, Madrid, España
- 5 Sociedad Española de Medicina y Seguridad del Trabajo, Madrid, España
- 6 Ministerio de Sanidad, Madrid, España
ISSN: 0214-9168, 1578-1879
Year of publication: 2022
Volume: 34
Issue: 4
Pages: 219-228
Type: Article
More publications in: Clínica e investigación en arteriosclerosis
Abstract
We present the Spanish adaptation of the 2021 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. The current guidelines besides the individual approach greatly emphasize on the importance of population level approaches to the prevention of cardiovascular diseases. Systematic global cardiovascular disease risk assessment is recommended in individuals with any major vascular risk factor. Regarding LDL-cholesterol, blood pressure, and glycemic control in patients with diabetes mellitus, goals and targets remain as recommended in previous guidelines. However, it is proposed a new, stepwise approach (steps 1 and 2) to treatment intensification as a tool to help physicians and patients pursue these targets in a way that fits patient profile. After step 1, considering proceeding to the intensified goals of step 2 is mandatory, and this intensification will be based on 10-year cardiovascular disease risk, lifetime cardiovascular disease risk and treatment benefit, comorbidities and patient preferences. The updated SCORE algorithm ?SCORE2, SCORE2-OP? is recommended in these guidelines, which estimates an individual's 10-year risk of fatal and non-fatal cardiovascular disease events (myocardial infarction, stroke) in healthy men and women aged 40-89 years. Another new and important recommendation is the use of different categories of risk according to different age groups (< 50, 50-69, ≥ 70 years).